"The reason for the increase from 240 to 300 is a mystery."
If we were always likely to get overwhelming efficacy @45% of 300, 135 patients, but not at 30% / 90 patients - I'd say the increase is a factor.
45% of 240 would have only been 108.
The answer to the above may simply be... maths.
Cell Therapy News/Articles, page-6521
-
- There are more pages in this discussion • 11,753 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.010(0.72%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.040M | 2.180M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 75722 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 29878 | 36 |
View Market Depth
| Last trade - 14.25pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |